Condition
Second Line Treatment
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Not Yet Recruiting2
Active Not Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07138885Phase 2Active Not Recruiting
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
NCT04522908Phase 2Completed
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
NCT06662877Phase 2Not Yet Recruiting
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
NCT06374160Not ApplicableNot Yet Recruiting
Exercise in Patients With Advanced Non-small Cell Lung Cancer
Showing all 4 trials